Dr. Mark Gebhardt, MD

• Surgical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Boston Children's Hospital, Orthopedic Surgery

  Fellowship Hospital, 1983

• Massachusetts General Hospital, Orthopedic Oncology

  Fellowship Hospital, 1983

• Harvard Medical School

  Residency Hospital, 1982

• University Health Center Of Pittsburgh

  Internship Hospital, 1977

• University Pittsburgh University Health Center

  Residency Hospital, 1977

• University Of Cincinnati College Of Medicine

  Medical School, 1975

• EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing Sarcoma Family of Tumors*, 2012-08-09

• MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32, 2013-01-22

• A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study, 2012-07-23

• Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-based Rigidity Analysis, 2015-02-27

• An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets, 2017-05-15

• Comparative Evaluation of Local Control Strategies in Localized Ewing Sarcoma of Bone: A Report from the Children's Oncology Group, 2014-09-23

• Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee, 2016-04-29

• Analysis of Multiple Sarcoma Expression Datasets: Implications for Classification, Oncogenic Pathway Activation and Chemotherapy Resistance, 2010-04-01